Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Clinical threshold for inflammatory bowel disease surgery may be too high

The clinical threshold for undertaking elective surgery to remove part or all of the colon (colectomy) for people with inflammatory bowel disease (IBD) may be too high, warn researchers in a study published on bmj.com.

31 Oct 2007

Infliximab scheduled treatment has proven to be an effective strategy in IBD patients

Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.

25 Oct 2007

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

Mesalamine linked to cancer protection for high risk inflammatory bowel disease patients

Researchers found that mesalamine use among patients with inflammatory bowel disease was associated with a decrease in incidence of colorectal cancer when comparing cases and controls.

16 Oct 2007

Interleukin-8, key marker for colorectal cancer treatment

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations.

10 Oct 2007

Specific immune deficiency pinpointed as likely cause of ulcerative colitis

In a series of mouse experiments, researchers at the Harvard School of Public Health (HSPH) have pinpointed a specific immune deficiency as the likely fundamental cause of ulcerative colitis, a chronic, sometimes severe inflammatory disease of the colon or large intestine that afflicts half a million Americans.

4 Oct 2007

Clostridium difficile infection is four times more likely to kill patients with inflammatory bowel disease

C difficile is an important cause of diarrhoea among inpatients, and the numbers of new cases of the infection have been steadily increasing in recent years.

27 Sep 2007

Biologic agents valuable treatment option for patients with inflammatory bowel disease

The use of biologic agents for the treatment of inflammatory bowel disease (IBD) may benefit patients, but doctors need to consider the potential associated side effects in determining treatment course, according to a consensus paper published in this month's issue of Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

26 Jul 2007

Discovery of gene variant that increases risk for Crohn's disease

Pediatrics researchers have identified a gene variant that raises a child's risk of Crohn's disease, a chronic and painful condition attributed to inflammation of the gastrointestinal tract.

19 Jul 2007

First-time link between food intolerance and illness

Researchers from University College London have found compelling evidence for the first time to link food intolerances and serious illness.

11 Jul 2007

New ulcerative colitis gene found

Researchers at The Hospital for Sick Children (SickKids), Mount Sinai Hospital and the University of Pittsburgh have identified a previously unsuspected gene found to be associated with ulcerative colitis.

9 Jul 2007

Leading-edge treatment for Crohn's disease at Pediatric Infusion Center

Seventeen-year-old Eliot Drieband explains what it's like to have Crohn's disease - a type of inflammatory bowel disease - in the same matter-of-fact way she describes preparing for an advanced placement exam, working on the school newspaper, starting an organ donor awareness club for teens and being a peer counselor for other kids facing chronic, life-altering illnesses.

9 Jul 2007

Long-term ulcerative colitis study shows Remicade responders maintained improvement

Findings presented at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

24 May 2007

Discovery of chemical profiles for infectious diarrhoea

Academics from the Universities of the West of England and Bristol have found that faeces from healthy people and those with infectious diarrhoea differ significantly in their chemical composition and could be used to diagnose quickly diseases such as Clostridium difficile (C. Diff.).

22 May 2007

Ulcerative colitis disruptive in relationships

Nearly three out of four ulcerative colitis (UC) sufferers (73 percent) responding to a new nationwide survey say not feeling well has become a normal part of life.

18 May 2007

Inflammatory bowel disease linked to nerve damage and other neurological problems

People with inflammatory bowel disease may also be at risk for developing nerve damage and other neurological problems, according to research that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 , May 5, 2007.

24 Apr 2007

Scientists find strong genetic link to Crohn's disease

An international team of scientists believe they have identified a number of genes that may indicate a pre-disposal to developing Crohn's disease and say their discovery confirms the suspicion that the inflammatory bowel ailment has a strong genetic link.

17 Apr 2007

New genetic risk factors for Crohn's disease

An international research team , including investigators from Massachusetts General Hospital (MGH) and the Broad Institute of Harvard University and Massachusetts Institute of Technology, has identified several novel genetic variations associated with the risk of Crohn's disease.

16 Apr 2007

Abbott opens biotech facility in Puerto Rico

"This new facility is a key milestone for Abbott as we move to focus our resources and future growth on biologic and potent-drug manufacturing," said Lawrence Kraus, vice president of manufacturing, global pharmaceutical operations, Abbott.

11 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007